VYNE Therapeutics (VYNE)
(Real Time Quote from BATS)
$0.36 USD
0.00 (-0.03%)
Updated Aug 6, 2025 01:44 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VYNE 0.36 0.00(-0.03%)
Will VYNE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VYNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYNE
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
VYNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
Other News for VYNE
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
VYNE Therapeutics (VYNE) Downgraded by HC Wainwright & Co. | VYNE Stock News
VYNE Downgraded to Neutral by H.C. Wainwright Analyst
VYNE Therapeutics Downgraded After Phase 2b Trial Setback